Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pathol Oncol Res ; 25(3): 1163-1174, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30499076

ABSTRACT

This study aimed to characterize endometrial cancer regarding cancer stem cells (CSC) markers, regulatory and differentiation pathways, tumorigenicity and glucose metabolism. Endometrial cancer cell line ECC1 was submitted to sphere forming protocols. The first spheres generation (ES1) was cultured in adherent conditions (G1). This procedure was repeated and was obtained generations of spheres (ES1, ES2 and ES3) and spheres-derived cells in adherent conditions (G1, G2 and G3). Populations were characterized regarding CD133, CD24, CD44, aldehyde dehydrogenase (ALDH), hormonal receptors, HER2, P53 and ß-catenin, fluorine-18 fluorodeoxyglucose ([18F]FDG) uptake and metabolism by NMR spectroscopy. An heterotopic model evaluated differential tumor growth. The spheres self-renewal was higher in ES3. The putative CSC markers CD133, CD44 and ALDH expression were higher in spheres. The expression of estrogen receptor (ER)α and P53 decreased in spheres, ERß and progesterone receptor had no significant changes and ß-catenin showed a tendency to increase. There was a higher 18F-FDG uptake in spheres, which also showed a lower lactate production and an oxidative cytosol status. The tumorigenesis in vivo showed an earlier growth of tumours derived from ES3. Endometrial spheres presented self-renewal and differentiation capacity, expressed CSC markers and an undifferentiated phenotype, showing preference for oxidative metabolism.


Subject(s)
Biomarkers, Tumor/metabolism , Endometrial Neoplasms/drug therapy , Glucose/metabolism , Neoplastic Stem Cells/pathology , Oxidative Stress , AC133 Antigen/metabolism , Animals , Apoptosis , Cell Proliferation , Endometrial Neoplasms/enzymology , Endometrial Neoplasms/pathology , Female , Humans , Hyaluronan Receptors/metabolism , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplastic Stem Cells/metabolism , Phenotype , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , beta Catenin/metabolism
2.
J Nutr Biochem ; 56: 183-192, 2018 06.
Article in English | MEDLINE | ID: mdl-29587241

ABSTRACT

A diet rich in fiber is associated with a low risk of developing colorectal cancer. Dietary fiber fermentation by intestinal microflora results in the production of butyrate, which has been reported as a chemopreventive agent and a histone deacetylase inhibitor (HDACi). Irinotecan is used as second-line treatment and induces adverse effects with serious life-threatening toxicities in at least 36% of patients. Our study intends to find a synergy that could improve the efficacy and decrease the toxicity of chemotherapy. Results demonstrate that milimolar concentrations of butyrate has an anti-proliferative effect in all three colon cancer cell lines under study, leading to a decrease on cell viability, expression of P21, P53 and ß-catenin, being able to modulate P-glycoprotein activity and to induce apoptosis by modulation of BAX/BCL-2 ratio. Combined therapy has a cytotoxic potential, resulting in a synergistic effect, and allows a reduction in irinotecan concentration needed to reduce IC50. This potential was verified in terms of cell viability and death, cell cycle and expression of P21 and P53. Butyrate and irinotecan act synergistically in the three cancer cell lines, despite the different genetic background and location, and inhibited tumor growth in a xenograft model. Butyrate is able to influence the mechanism of LS1034 cell line chemoresistance. Butyrate in combination with chemotherapeutic agents has an important role for the treatment of colorectal cancer. Such understanding can guide decisions about which patients with colorectal cancer may benefit from therapy with butyrate demonstrating the important role of diet in colorectal cancer treatment.


Subject(s)
Antineoplastic Agents/administration & dosage , Butyrates/administration & dosage , Colonic Neoplasms/metabolism , Irinotecan/administration & dosage , Animals , Apoptosis , Cell Line, Tumor , Cell Proliferation , Cell Survival , Colon/metabolism , Colonic Neoplasms/drug therapy , Dietary Fiber , Drug Synergism , Fermentation , Gastrointestinal Microbiome , Histone Deacetylases/metabolism , Humans , Inhibitory Concentration 50 , Mice , Mice, Inbred BALB C , Neoplasm Transplantation
SELECTION OF CITATIONS
SEARCH DETAIL
...